By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Waters today reported revenues grew 14 percent year over year in the second quarter, but missed analysts' estimates on soft sales to government and academic customers.

For the three months ended July 2, the company posted $447.6 million in revenues, up from $391.1 million a year ago, but short of Wall Street's consensus estimate of $451.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.